Vulvar Cancer: Diagnosis, Treatment, and Specialist Access
Vulvar cancer is a rare gynecologic cancer most often diagnosed in older women, with early detection and specialist surgical planning playing a major role in preserving function and improving outcomes.
- Function-Preserving Surgical Techniques
- Sentinel Lymph Node Expertise
- Specialist Second Opinions
- Most Common In
- Women over 65
- Most Common Subtype
- Squamous Cell Carcinoma (~90%)
- Key Diagnostic Tool
- Vulvar Biopsy
- Advanced Therapies
- Sentinel Node Biopsy, Immunotherapy
Condition Overview
Vulvar cancer develops in the external female genital tissue, including the labia, clitoris, and surrounding skin. It most often presents as a persistent lump, sore, or area of skin change that does not heal.
The majority of vulvar cancers are squamous cell carcinomas, which can be either HPV-related, more common in younger women, or HPV-independent and associated with chronic vulvar skin conditions in older women. Less common subtypes include vulvar melanoma and Paget's disease of the vulva.
Because early vulvar changes can resemble benign skin conditions, diagnosis is sometimes delayed. Prompt biopsy of any persistent or changing vulvar lesion, along with access to specialists experienced in function-preserving surgical techniques, supports both better outcomes and quality of life.
Types and Subtypes
Vulvar cancer is classified by cell origin, which influences both biology and treatment approach.
Symptoms and Signs
Vulvar cancer symptoms often involve visible or palpable changes to the vulvar skin that persist over time.
Causes and Risk Factors
Vulvar cancer arises through two main pathways: persistent HPV infection and chronic vulvar skin conditions.
Diagnosis and Investigations
Diagnosis is based on direct examination and biopsy of suspicious vulvar lesions, followed by imaging to assess disease extent.
Staging and Risk Groups
Vulvar cancer staging is based on tumor size, depth of invasion, and spread to lymph nodes or distant sites.
Standard Treatment Options
Treatment is guided by tumor size, depth, location, and lymph node status, with a strong emphasis on preserving function where possible.
Advanced & Emerging Therapies
For recurrent or advanced vulvar cancer, systemic treatment options continue to expand, particularly for HPV-related disease.
Immunotherapy
Checkpoint Inhibitors
Used in select recurrent or metastatic vulvar cancers, particularly those with high PD-L1 expression.
Precision Medicine
BRAF/MEK or Immunotherapy for Vulvar Melanoma
Targeted and immune-based therapy options for vulvar melanoma with relevant mutations.
Targeted Therapy
Antibody-Drug Conjugates
Being explored in HPV-related gynecologic cancers including vulvar cancer for recurrent disease.
Biomarkers & Precision Medicine
Molecular and pathology markers help guide diagnosis, prognosis, and treatment decisions in vulvar cancer.
When a Second Opinion May Be Important
Specialist input can be particularly valuable in several vulvar cancer scenarios.
Clinical Trials and Research
Prognosis & Outcomes
Prognosis in vulvar cancer is closely linked to tumor size, depth of invasion, and especially lymph node status at diagnosis.
Supportive Care and Living With Vulvar Cancer
Supportive care for vulvar cancer addresses both physical recovery from treatment and emotional wellbeing.
How CancerFax Helps You Explore Treatment Options
CancerFax helps vulvar cancer patients access gynecologic oncology second opinions, coordinate surgical and radiation planning, and explore immunotherapy or clinical trial options for recurrent disease.
Get a free case reviewFrequently Asked Questions
Common early signs include persistent itching, a lump or thickened patch of skin, or a sore that doesn't heal on the vulva. Changes in skin color are also common.
Some vulvar cancers are linked to persistent HPV infection, more often in younger women, while others are HPV-independent and associated with chronic vulvar skin conditions, more common in older women.
Surgery is the main treatment for most vulvar cancers, often combined with sentinel lymph node biopsy. Radiation, sometimes with chemotherapy, is used for higher-risk or more advanced disease.
This is a technique that identifies and removes only the first lymph nodes that drain the tumor, helping determine if cancer has spread while reducing the need for more extensive lymph node removal.
Surgery and radiation can affect vulvar sensation and sexual function. Discussing these concerns with your care team before treatment can help with planning and support afterward.
This is a rare condition involving abnormal glandular cells in vulvar skin, which can sometimes be associated with an underlying cancer and requires careful evaluation.
Early-stage vulvar cancer often responds well to treatment. Outcomes for more advanced or recurrent disease depend on lymph node status and tumor characteristics, and benefit from specialist management.
Immunotherapy is approved for select recurrent or metastatic vulvar cancers, particularly when PD-L1 is expressed on the tumor.
Follow-up typically includes regular vulvar and groin examinations, with frequency and additional imaging tailored to your stage and recurrence risk.
Yes. CancerFax can help you get your pathology and imaging reports reviewed by gynecologic oncology specialists, coordinate a second opinion, and explore immunotherapy or clinical trial access for recurrent or advanced vulvar cancer, including coordination with international centers where relevant.
Get Expert Guidance on Your Vulvar Cancer Diagnosis
Send your pathology and imaging reports to CancerFax for specialist gynecologic oncology review.